JUPITER NEUROSCIENCES, INC. Financials
JUPITER NEUROSCIENCES, INC. (JUNS) reported $22K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage operations are funded externally while losses consume cash faster than revenue can support.
In FY2025, operating cash flow was-$5.4M while financing supplied$5.4M , so external capital—not operating receipts—maintained liquidity. Cash remained near$3.8M , but the current ratio fell from 2.3x in FY2024 to 0.7x in FY2025, showing that the liquidity cushion narrowed as obligations grew.
FY2025 revenue was only
Equity shifted from
Financial Health Signals
JUPITER NEUROSCIENCES, INC. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
JUPITER NEUROSCIENCES, INC. scores -14.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.8M) relative to total liabilities ($7.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
JUPITER NEUROSCIENCES, INC. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
JUPITER NEUROSCIENCES, INC. reported a net loss of $8.6M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
JUPITER NEUROSCIENCES, INC. reported an operating loss of $8.9M against $66K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
JUPITER NEUROSCIENCES, INC. generated $22K in revenue in fiscal year 2025.
JUPITER NEUROSCIENCES, INC. reported -$8.6M in net income in fiscal year 2025. This represents a decrease of 254.4% from the prior year.
JUPITER NEUROSCIENCES, INC. earned -$0.25 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
JUPITER NEUROSCIENCES, INC. held $3.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
JUPITER NEUROSCIENCES, INC.'s gross margin was 80.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
JUPITER NEUROSCIENCES, INC. invested $2.1M in research and development in fiscal year 2025. This represents an increase of 323.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
JUNS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | N/A | $22K | $0 | N/A |
| Cost of Revenue | N/A | $4K | N/A | N/A |
| Gross Profit | N/A | $18K | N/A | N/A |
| R&D Expenses | N/A | $2.1M+323.5% | $493K | N/A |
| SG&A Expenses | N/A | $6.8M+163.2% | $2.6M | N/A |
| Operating Income | N/A | -$8.9M-188.2% | -$3.1M | N/A |
| Interest Expense | N/A | $66K-73.4% | $248K+13.6% | $219K |
| Net Income | N/A | -$8.6M-254.4% | -$2.4M | N/A |
| EPS (Diluted) | — | -$0.25 | -$0.08+55.6% | -$0.18 |
Not reported in any period shown, so not listed: Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JUNS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $5.6M-10.3% | $6.2M+4074.1% | $149K |
| Current Assets | $4.8M+3.8% | $4.7M+16081.0% | $29K |
| Cash & Equivalents | $3.8M+0.5% | $3.8M+13136.6% | $28K |
| Inventory | $160K | N/A | N/A |
| Accounts Receivable | $3K | N/A | N/A |
| Total Liabilities | $7.4M+264.3% | $2.0M-65.9% | $5.9M |
| Current Liabilities | $7.4M+268.1% | $2.0M-65.2% | $5.8M |
| Total Equity | -$1.8M-143.9% | $4.2M+171.9% | -$5.8M |
| Retained Earnings | -$34.7M-33.2% | -$26.0M-10.3% | -$23.6M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
JUNS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$7.2M | -$5.4M-38.4% | -$3.9M-713.2% | -$481K |
| Financing Cash Flow | N/A | $5.4M-29.0% | $7.7M+1619.6% | $445K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JUNS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Gross Margin | 80.6% | N/A | N/A |
| Operating Margin | -40873.2% | N/A | N/A |
| Net Margin | -39662.8% | N/A | N/A |
| Return on Equity | N/A | -58.5% | N/A |
| Return on Assets | -155.4%-116.0pp | -39.3% | N/A |
| Current Ratio | 0.65-1.7x | 2.31+2.3x | 0.01 |
| Debt-to-Equity | N/A | 0.49 | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$1.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.65), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where JUPITER NEUROSCIENCES, INC. Ranks
Frequently Asked Questions
What is JUPITER NEUROSCIENCES, INC.'s annual revenue?
JUPITER NEUROSCIENCES, INC. (JUNS) reported $22K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is JUPITER NEUROSCIENCES, INC. profitable?
No, JUPITER NEUROSCIENCES, INC. (JUNS) reported a net income of -$8.6M in fiscal year 2025.
What is JUPITER NEUROSCIENCES, INC.'s gross margin?
JUPITER NEUROSCIENCES, INC. (JUNS) had a gross margin of 80.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is JUPITER NEUROSCIENCES, INC.'s operating cash flow?
JUPITER NEUROSCIENCES, INC. (JUNS) recorded an outflow of $5.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are JUPITER NEUROSCIENCES, INC.'s total assets?
JUPITER NEUROSCIENCES, INC. (JUNS) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does JUPITER NEUROSCIENCES, INC. spend on research and development?
JUPITER NEUROSCIENCES, INC. (JUNS) invested $2.1M in research and development during fiscal year 2025.
What is JUPITER NEUROSCIENCES, INC.'s current ratio?
JUPITER NEUROSCIENCES, INC. (JUNS) had a current ratio of 0.65 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is JUPITER NEUROSCIENCES, INC.'s return on assets (ROA)?
JUPITER NEUROSCIENCES, INC. (JUNS) had a return on assets of -155.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is JUPITER NEUROSCIENCES, INC.'s cash runway?
Based on fiscal year 2025 data, JUPITER NEUROSCIENCES, INC. (JUNS) had $3.8M in cash against an annual operating cash burn of $5.4M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is JUPITER NEUROSCIENCES, INC.'s debt-to-equity ratio negative or not reported?
JUPITER NEUROSCIENCES, INC. (JUNS) has negative shareholder equity of -$1.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is JUPITER NEUROSCIENCES, INC.'s Altman Z-Score?
JUPITER NEUROSCIENCES, INC. (JUNS) has an Altman Z-Score of -14.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is JUPITER NEUROSCIENCES, INC.'s Piotroski F-Score?
JUPITER NEUROSCIENCES, INC. (JUNS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are JUPITER NEUROSCIENCES, INC.'s earnings high quality?
JUPITER NEUROSCIENCES, INC. (JUNS) reported a net loss of $8.6M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can JUPITER NEUROSCIENCES, INC. cover its interest payments?
JUPITER NEUROSCIENCES, INC. (JUNS) reported an operating loss of $8.9M against $66K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.